Asset sale Completed

Eli Lilly and Company acquisition of Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program

Announced 23 Jun 2026 · OTC: SGMOQ

Advisers

Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program

Target

Not disclosed

Other advisers

Financial adviser
Target
Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program
Acquirer
Eli Lilly and Company
Seller
Sangamo Therapeutics
Target based in
United States
Buyer based in
United States
Seller based in
United States
Completed
Sep 2026
Sector
Biotech
Tags
Biotech, Life Sciences

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.